Regeneron: Dupixent expansion meets Eylea patent cliff - Biotech quality test

5-year stock timeline

Key Points

From recommendation (January 31, 2026)

• Q4 2025: Sales +3% to 3.9 billion USD, adjusted EPS USD 11.44 (consensus USD 10.56) - Dupixent grows 32% to 17.8 bn. USD Annual turnover
• Eylea HD +66% to 506 million USD, while Legacy-Eylea slumps -52% due to biosimilar competition and compounding pressure
• Libtayo 425 million USD (+13% YoY), market leader in advanced forms of skin cancer with expansion into cervical cancer
• Net profit 1.2 billion USD, free cash flow 4.1 billion USD (2025), net liquidity 16.2 bn. USD - 3.4 billion USD Share buybacks

Investment Thesis

From recommendation (January 31, 2026)

Regeneron's Q4 beat shows operational stability driven by Dupixent growth, while Eylea HD only partially compensates for legacy erosion. The pipeline will deliver at least four FDA approvals by the end of 2026, including three new active ingredients, but the patent cliff from 2031 at Dupixent casts a shadow ahead - Sanofi has already admitted that it will not be able to close the sales gap. With a P/E ratio of 17.5, a 31% net margin and solid balance sheet quality (equity ratio 78%), the share is trading below analysts' consensus of USD 832. The valuation reflects both the essential nature of the core products (blindness prevention, severe dermatitis) and structural risks due to Medicare price negotiations and product concentration. For patient investors, the combination of FDA catalysts, institutional buying and quality management offers an interesting entry point - provided the regulatory uncertainties of the Trump era are priced in.

Key risks and downside factors

Regeneron competes across ophthalmology, oncology, and immunology against formidable players like Amgen, Roche/Genentech, Novartis, AbbVie, and Eli Lilly. The real pressure points are in marketed biologics—particularly in ophthalmology and lipid/immune treatments—where pipeline overlap means larger competitors can lean on scale to squeeze pricing and market access. What matters operationally: the company carries meaningful product concentration risk, depends on key partnerships, faces patent cliffs and biosimilar competition, and remains exposed to clinical disappointments and regulatory headwinds that could meaningfully compress both revenue and margins.

• A handful of co-developed or partnered drugs account for a substantial portion of sales, which means that partner disputes or the loss of exclusivity could meaningfully erode revenue. The business carries meaningful concentration risk here.
• Patent expiry and biosimilar competition create real headwinds for biologics across ophthalmology and beyond. As exclusivity periods end, biosimilar entrants and IP litigation reshape both market share and pricing power. It's worth watching how individual franchises navigate this transition—some manage it better than others.
• Clinical and R&D failures pose a meaningful risk. Late-stage trial setbacks or regulatory hurdles for pipeline candidates could meaningfully impair both growth trajectory and valuation.
• Pricing and reimbursement pressure from payor restrictions, reimbursement changes, or government pricing reforms in major markets can compress margins and limit uptake.

Competitive landscape

Regeneron competes in biologics against established players like Amgen, AbbVie, Roche/Genentech, Eli Lilly, Pfizer and AstraZeneca. The company has built real strengths—marketed biologics and proprietary discovery platforms that work. But those advantages matter less in ophthalmology, oncology and immunology, where competition is thick and new entrants keep arriving. What keeps you up at night: patent cliffs, the occasional clinical or regulatory surprise, pricing pressure that never really stops, and the fact that a meaningful chunk of revenue leans on a small number of products and partnerships.

Catalysts

From recommendation (January 31, 2026)

• FDA decision on new Eylea HD filler manufacturer in Q2 2026 after Catalent delays
• Dupixent COPD approval (November 2025) and Libtayo cervical cancer expansion each unlock 2+ billion USD peak sales potential
• At least three new molecular entities with FDA approvals in the next 12 months
• GLP-1 agonist data H1 2026 as diversification in obesity market
• Possible agreement with Trump administration on drug prices along the lines of other pharmaceutical companies

Analysis

From recommendation (January 31, 2026)

Performance Figures of Regeneron Pharmaceuticals Inc

in USD

Historical valuation trends

How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.

Frequently Asked Questions

From recommendation (January 31, 2026)

Key Metrics

From recommendation (January 31, 2026)

Valuation Metrics

Profitability Metrics

Growth Metrics

Dividend history

Long-term record of paid dividends (amount per share and dividend yield at the time of payment).

Earnings history & estimates

Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.

Key financial figures

All figures in USD

Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.